Clinuvel Pharmaceuticals Limited
CLVLF
$7.96
-$0.1583-1.95%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -2.75% | -35.43% | |||
| Total Other Revenue | -2.74% | -23.22% | |||
| Total Revenue | -2.75% | -34.55% | |||
| Cost of Revenue | -2.75% | -41.20% | |||
| Gross Profit | -2.75% | -33.84% | |||
| SG&A Expenses | -2.75% | -5.28% | |||
| Depreciation & Amortization | -2.75% | 8.99% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.75% | -4.85% | |||
| Operating Income | -2.75% | -52.28% | |||
| Income Before Tax | -2.75% | -37.84% | |||
| Income Tax Expenses | -2.75% | -28.50% | |||
| Earnings from Continuing Operations | -2.75% | -42.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.75% | -42.06% | |||
| EBIT | -2.75% | -52.28% | |||
| EBITDA | -2.75% | -50.75% | |||
| EPS Basic | -2.76% | -42.00% | |||
| Normalized Basic EPS | -2.73% | -37.79% | |||
| EPS Diluted | -2.77% | -41.78% | |||
| Normalized Diluted EPS | -2.84% | -37.57% | |||
| Average Basic Shares Outstanding | 0.00% | -0.11% | |||
| Average Diluted Shares Outstanding | 0.00% | -0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 0.00% | -- | |||